P2X7 RECEPTOR TARGETED THERAPY
The invention relates to methods of treating cancer, particular cancers which have developed a resistance to chemotherapeutics. Particularly, the invention relates to a method of treating cancer in an individual who has not responded, or no longer responds, to chemotherapy, the method comprising pro...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English |
Published |
11.08.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention relates to methods of treating cancer, particular cancers which have developed a resistance to chemotherapeutics. Particularly, the invention relates to a method of treating cancer in an individual who has not responded, or no longer responds, to chemotherapy, the method comprising providing an individual who has not responded, or no longer responds, to a chemotherapeutic agent; providing in the individual a whole antibody or a fragment thereof including a variable domain for binding to a P2X7 receptor that is expressed by the individual; wherein the P2X7 receptor has an impaired response to ATP such that it is unable to form an apoptotic pore under normal physiological conditions, thereby treating cancer in the individual. |
---|---|
Bibliography: | Application Number: US202017618849 |